FEELM
21.11.2022 12:55:43 CET | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, was pleased to have its European Division Director, Echo Liu, deliver a keynote speech at the UKVIA Vaping Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005424/en/
Echo presenting a speech at the UKVIA. (Photo: Business Wire)
In her address to 300 delegates at the UK’s largest dedicated business-to-business vaping conference, Echo Liu reiterated FEELM’s belief that innovation is key to the future success of the industry: finding solutions to the major challenges of customer satisfaction, harm reduction, and Climate Change. The highlights of her speech included:
“By every metric – flavour, taste, noise, or even harm reduction – our patented FEELM ceramic coil has revolutionised the performance of our clients’ products. FEELM Max, the world’s first ceramic coil disposable pod solution, introduces a number of breakthrough innovations, including 25% more puffs with the same e-liquid volume versus other coil technologies. It also resolves issues like inconsistent flavour and dry burning which are commonly seen in other disposable products. Thanks to the Constant Output Control and Patented Flavour-Lock Technology that FEELM Max adopts, we have achieved over 95% flavour consistency and a 30%-smoother vapour. We believe FEELM Max is taking the vaping experience to the next level as our harm reduction outperforms mainstream disposable products by 46%.”
In addition, the semi-translucent mouth-piece that FEELM Max recently introduced allows our users to check their e-liquid volume at all times.
“On top of our 14 R&D centres across the world, we recently opened China’s first PMTA-standard testing lab to help our brand partners improve their entry to the US market and complete their application process more easily – building on the success of our client Njoy, the first closed pod system to receive PMTA approval in the US.”
“Given the continued and increasing focus on ESG issues from our clients and their consumers, we are also working on a range of products that are made from eco-friendly materials. Our aim is to improve recyclability while developing biodegradable products which can decompose naturally. Driven by FEELM's latest ceramic coil technology, our new “Green Series” is leading the way. Batteries can be dismantled with ease for users to recycle, while other components can easily decompose. All of this is helping to bring down our carbon footprint while meeting the needs of our eco-conscious clients, and their customers. This is also proof of how we stick to our mission – atomization makes life better.”
In closing, Echo Liu welcomed the UKVIA’s first ever Economic Impact Assessment of the vaping industry, which FEELM hopes will prove how important the industry is to the UK economy and improving the public health of the nation by encouraging more smokers to switch.
ENDS
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
